TherapeuticsMD - TXMD Stock Forecast, Price & News

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for TherapeuticsMD in the last year. There are currently 2 hold ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" TXMD shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in TXMD, but not buy additional shares or sell existing shares.
View TXMD analyst ratings or view top-rated stocks.

2 Wall Street analysts have issued twelve-month price objectives for TherapeuticsMD's stock. Their TXMD share price forecasts range from $125.00 to $125.00. On average, they expect the company's share price to reach $125.00 in the next twelve months. This suggests a possible upside of 2,303.8% from the stock's current price.
View analysts price targets for TXMD or view top-rated stocks among Wall Street analysts.

TherapeuticsMD's stock was trading at $5.59 on January 1st, 2023. Since then, TXMD shares have decreased by 7.0% and is now trading at $5.20.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Thursday, March 9th 2023.
View our TXMD earnings forecast.

TherapeuticsMD, Inc. (NASDAQ:TXMD) issued its earnings results on Monday, November, 14th. The company reported ($3.13) EPS for the quarter, missing analysts' consensus estimates of ($2.04) by $1.09. The business had revenue of $20.92 million for the quarter, compared to analysts' expectations of $30.20 million.

TherapeuticsMD shares reverse split before market open on Monday, May 9th 2022. The 1-50 reverse split was announced on Monday, May 9th 2022. The number of shares owned by shareholders was adjusted after the market closes on Monday, May 9th 2022. An investor that had 100 shares of stock prior to the reverse split would have 2 shares after the split.

Based on aggregate information from My MarketBeat watchlists, some companies that other TherapeuticsMD investors own include OPKO Health (OPK), Verastem (VSTM), Teva Pharmaceutical Industries (TEVA), Inovio Pharmaceuticals (INO), NVIDIA (NVDA), Sorrento Therapeutics (SRNE), Gilead Sciences (GILD), Cleveland-Cliffs (CLF), Novavax (NVAX) and Micron Technology (MU).

TherapeuticsMD trades on the NASDAQ under the ticker symbol "TXMD."

TherapeuticsMD's stock is owned by many different retail and institutional investors. Top institutional shareholders include Simplex Trading LLC (0.00%), XR Securities LLC (0.00%), XR Securities LLC (0.00%), Equitec Proprietary Markets LLC (0.00%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Brian Bernick, Cooper C Collins, Edward Borkowski, Gail K Naughton, James Darecca, Marlan D Walker, Marlan D Walker, Michael C Donegan, Michael C Donegan, Paul Bisaro, Robert G Finizio, Rubric Capital Management Lp, Tommy G Thompson and Tommy G Thompson.
View institutional ownership trends.

Shares of TXMD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of TXMD stock can currently be purchased for approximately $5.20.

TherapeuticsMD (NASDAQ:TXMD) has a market capitalization of $48.98 million and generates $86.95 million in revenue each year. The company earns $-172,410,000.00 in net income (profit) each year or ($1.43) on an earnings per share basis.

The company employs 416 workers across the globe.

TherapeuticsMD's mailing address is 951 Yamato Road Suite 220, BOCA RATON FL, 33431. The official website for the company is www.therapeuticsmd.com. The company can be reached via phone at (561) 961-1900, via email at shareholder@broadridge.com, or via fax at 561-431-3389.